Asia
Fudan-Zhangjiang Bio-Pharma's Profit Jumps 189% in Q1
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349, SHA:688505) posted net profit attributable to shareholders of 7.7 million yuan for the first quarter, up 189% from 2.7 million yuan a year earlier, according to a Wednesday Hong Kong bourse filing.Hong Kong-listed shares of the biotech firm were up nearly 2% in recent trade.Earnings per share came in at 0.01 yuan, compared with a near-zero figure a year earlier.Revenue fell 17% to 149.1 million yuan from 179.9 million yuan in the prior-year period.
HKG:1349SHA:688505
